Table 4.
Hydrophobic moiety | Active agent | Particle size (nm) | Zeta-potential (mV) | Ref. |
---|---|---|---|---|
deoxycholic acid | DNA | 162 ± 18 a | [145] | |
~300 b | ||||
130–300 a | [146] | |||
cholesterol | Epirubicin | 417 ± 18 a | [147] | |
338–473 b | ||||
6-O-cholesterol | All-trans retinoic acid | 100–240 a | +24.5 to +25.9 a | [148] |
192–222 b | ||||
stearyl | Paclitaxel | 28.1–74.6 a | +39.0 to +53.2 a | [149] |
35.8–175.1 b | +44.0 to +58.7 b | |||
Doxorubicin | 272–322 a | +34.2 to +57.1 a | [150] | |
305–355 b | +51.8 to +69.1 b | |||
27.4 ± 2.4 a | +52 ± 3 a | [151] | ||
20.4 ± 1.1 b | +53.1 ± 14.4 b | |||
stearyl + doxorubicin | Doxorubicin | 40.1–105.8 b | +32.0 to +43.7 b | [152] |
Acyl | Rifampin | 154–181 a | [153] | |
163–210 b | ||||
Vitamin C | 444–487 a | +10.2 to +28.9 a | [154] | |
216–288 b | +5.9 to +18.4 b | |||
N,O6-acetyl + steroid | Steroids | 197–358 b | +7 to +22.7 b | [155] |
N,O6-acetyl + tocopherol | Vitamin E | 275 ± 5 b | +14.9 ± 0.7 b | |
phthaloyl | Camptothecin | ~170 a | [156] | |
~200–267 b | ||||
~50–100 a | ||||
~100–250 b | [157] | |||
All-trans retinoic acidPrednisone acetate | ~50–100 a | [158,159] | ||
~80–160 b | ||||
89.8 a | ||||
143.3 b | ||||
polycaprolactone, (Chitosan-grafted) | 7-Ethyl-10-hydroxy-camptothecin | 47–113 a | +26.7 to +50.8 a | [160] |
63–152 b | +25.6 to +48.8 b | |||
BSA | 168.44 b | [161] | ||
200.7 b | ||||
435 ± 25 a | ||||
Paclitaxel | 408–529 b | +27.5 ± 1.1 a | [162] | |
61.4–108.6 a | +30.9 to +33.3 b | |||
5-Fluorouracil | 67.9–96.7 b | +18.9 to +43.1 b | [163] | |
N-acetyl histidine | Doxorubicin | 218 a | +40.1 ± 2.8 a | [164] |
185.3–218.3 b | +36.3 to +40.1 b |
a Unloaded particle; b loaded particle; * 5 mg/mL.